The National Heart, Lung, and Blood Institute (NHLBI) recently awarded The Texas Heart Institute (THI) a two-year, $1.14 million grant to develop a novel, first-in-class drug to treat cardiovascular disease (CVD) as a significant improvement to current treatm…